Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.

Hata A, Katakami N, Tanaka K, Takeshita J, Matsumoto T, Monden K, Nagata K, Masago K, Kaji R, Fujita S, Tachikawa R, Otsuka K, Otsuka K, Tomii K.

Anticancer Res. 2014 Jan;34(1):275-81.

PMID:
24403474
[PubMed - indexed for MEDLINE]
2.

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.

Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R.

Cancer Chemother Pharmacol. 2014 Mar;73(3):467-73. doi: 10.1007/s00280-013-2372-x. Epub 2014 Jan 4.

PMID:
24390424
[PubMed - indexed for MEDLINE]
3.

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH.

Ann Oncol. 2014 Jan;25(1):132-8. doi: 10.1093/annonc/mdt489.

PMID:
24356624
[PubMed - indexed for MEDLINE]
4.

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R.

J Clin Oncol. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21.

PMID:
24145346
[PubMed - indexed for MEDLINE]
5.

Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab.

Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, Powell B, Bruno R.

J Clin Pharmacol. 2014 Mar;54(3):253-7. doi: 10.1002/jcph.191. Epub 2013 Oct 22.

PMID:
24122760
[PubMed - indexed for MEDLINE]
6.

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.

Ciuleanu T, Tsai CM, Tsao CJ, Milanowski J, Amoroso D, Heo DS, Groen HJ, Szczesna A, Chung CY, Chao TY, Middleton G, Zeaiter A, Klingelschmitt G, Klughammer B, Thatcher N.

Lung Cancer. 2013 Nov;82(2):276-81. doi: 10.1016/j.lungcan.2013.08.002. Epub 2013 Aug 13.

PMID:
23992877
[PubMed - indexed for MEDLINE]
Free Article
7.

Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.

Shah M, Winfree KB, Peterson P, Gruschkus SK, Eaddy M, Green MR.

Lung Cancer. 2013 Oct;82(1):121-7. doi: 10.1016/j.lungcan.2013.07.021. Epub 2013 Aug 7.

PMID:
23973203
[PubMed - indexed for MEDLINE]
Free Article
8.

Baseline tumour measurements predict survival in advanced non-small cell lung cancer.

Gerber DE, Dahlberg SE, Sandler AB, Ahn DH, Schiller JH, Brahmer JR, Johnson DH.

Br J Cancer. 2013 Sep 17;109(6):1476-81. doi: 10.1038/bjc.2013.472. Epub 2013 Aug 13.

PMID:
23942074
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.

Tamiya M, Tamiya A, Yamadori T, Nakao K, Asami K, Yasue T, Otsuka T, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Kawase I, Hirashima T.

Med Oncol. 2013;30(3):676. doi: 10.1007/s12032-013-0676-7. Epub 2013 Aug 8.

PMID:
23925664
[PubMed - indexed for MEDLINE]
11.

Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer.

Socinski MA, Govindan R, Spigel D.

Clin Adv Hematol Oncol. 2012 Oct;10(10 Suppl 18):1-16.

PMID:
23187688
[PubMed - indexed for MEDLINE]
12.

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.

Eberhardt WE, Mitchell P, Schiller JH, Brown MP, Thomas M, Mills G, Jehl V, Urva SR, De Leo JJ, Gogov S, Papadimitrakopoulou V.

Invest New Drugs. 2014 Feb;32(1):123-34. doi: 10.1007/s10637-013-9958-3. Epub 2013 Apr 12.

PMID:
23579358
[PubMed - indexed for MEDLINE]
13.

[Analysis of drug therapy of lung cancer in Hungary].

Moldvay J, Rokszin G, Abonyi-Tóth Z, Katona L, Kovács G.

Magy Onkol. 2013 Mar;57(1):33-8. doi: MagyOnkol.2013.57.1.33. Epub 2012 Dec 20. Hungarian.

PMID:
23573520
[PubMed - indexed for MEDLINE]
Free Article
14.

Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.

Urata Y, Okamoto I, Takeda M, Hattori Y, Okuno K, Shimada T, Kurata T, Kaneda H, Miyazaki M, Terashima M, Tanaka K, Morita S, Nakagawa K, Negoro S, Satouchi M.

Cancer. 2013 Jun 15;119(12):2275-81. doi: 10.1002/cncr.28048. Epub 2013 Apr 4.

PMID:
23558513
[PubMed - indexed for MEDLINE]
15.

Safety of cupping during bevacizumab therapy.

Klempner SJ, Costa DB, Wu PA, Ariyabuddhiphongs KD.

J Altern Complement Med. 2013 Aug;19(8):729-31. doi: 10.1089/acm.2011.0791. Epub 2013 Feb 4.

PMID:
23379829
[PubMed - indexed for MEDLINE]
16.

[Brain metastases of non small cell lung cancers: systemic treatments].

Chaubet-Houdu M, Besse B.

Bull Cancer. 2013 Jan 1;100(1):95-8. doi: 10.1684/bdc.2012.1688. Review. French.

PMID:
23376611
[PubMed - indexed for MEDLINE]
17.

Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.

Bonomi PD, Mace J, Mandanas RA, Min M, Olsen M, Youssoufian H, Katz TL, Sheth G, Lee HJ.

J Thorac Oncol. 2013 Mar;8(3):338-45. doi: 10.1097/JTO.0b013e318282ded5.

PMID:
23370316
[PubMed - indexed for MEDLINE]
18.

[Efficacy of chemotherapy with carboplatin-paclitaxel plus bevacizumab for previously treated patients with advanced non-small cell carcinoma].

Maki S, Igawa S, Otani S, Nagashima Y, Kimura M, Hiyoshi Y, Ishihara M, Kasajima M, Katono K, Takakura A, Kubota M, Masuda N.

Gan To Kagaku Ryoho. 2012 Dec;39(13):2509-12. Japanese.

PMID:
23235169
[PubMed - indexed for MEDLINE]
19.

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.

Saijo N.

Yonsei Med J. 2013 Jan 1;54(1):1-14. doi: 10.3349/ymj.2013.54.1.1. Review.

PMID:
23225792
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience.

Jardim DL, Gagliato Dde M, Ribeiro KB, Shimada AK, Katz A.

Drugs R D. 2012 Dec 1;12(4):207-16. doi: 10.2165/11636760-000000000-00000.

PMID:
23199211
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk